Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Saved in:
| Title: | Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. |
|---|---|
| Authors: | Rediti M; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium., Fernandez-Martinez A; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Venet D; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium., Rothé F; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium., Hoadley KA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Parker JS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Singh B; White Plains Hospital, White Plains, NY, USA., Campbell JD; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA., Ballman KV; Alliance Statistics and Data Management Center, Weill Cornell Medicine, New York, NY, USA., Hillman DW; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA., Winer EP; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., El-Abed S; Breast International Group, Brussels, Belgium., Piccart M; Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium., Di Cosimo S; Integrated biology platform unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Symmans WF; Department of Pathology, University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA., Krop IE; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Salgado R; Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Loi S; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Pusztai L; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Perou CM; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Carey LA; Division of Hematology-Oncology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Sotiriou C; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium. christos.sotiriou@hubruxelles.be. |
| Source: | Nature communications [Nat Commun] 2023 Nov 03; Vol. 14 (1), pp. 7053. Date of Electronic Publication: 2023 Nov 03. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37923752 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Rediti+M%22">Rediti M</searchLink>; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Fernandez-Martinez+A%22">Fernandez-Martinez A</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Venet+D%22">Venet D</searchLink>; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Rothé+F%22">Rothé F</searchLink>; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Hoadley+KA%22">Hoadley KA</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Parker+JS%22">Parker JS</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Singh+B%22">Singh B</searchLink>; White Plains Hospital, White Plains, NY, USA.<br /><searchLink fieldCode="AU" term="%22Campbell+JD%22">Campbell JD</searchLink>; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA.<br /><searchLink fieldCode="AU" term="%22Ballman+KV%22">Ballman KV</searchLink>; Alliance Statistics and Data Management Center, Weill Cornell Medicine, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Hillman+DW%22">Hillman DW</searchLink>; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA.<br /><searchLink fieldCode="AU" term="%22Winer+EP%22">Winer EP</searchLink>; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22El-Abed+S%22">El-Abed S</searchLink>; Breast International Group, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Piccart+M%22">Piccart M</searchLink>; Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Di+Cosimo+S%22">Di Cosimo S</searchLink>; Integrated biology platform unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Symmans+WF%22">Symmans WF</searchLink>; Department of Pathology, University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Krop+IE%22">Krop IE</searchLink>; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Salgado+R%22">Salgado R</searchLink>; Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Loi+S%22">Loi S</searchLink>; Division of Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Pusztai+L%22">Pusztai L</searchLink>; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Perou+CM%22">Perou CM</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Carey+LA%22">Carey LA</searchLink>; Division of Hematology-Oncology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Sotiriou+C%22">Sotiriou C</searchLink>; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium. christos.sotiriou@hubruxelles.be. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2023 Nov 03; Vol. 14 (1), pp. 7053. <i>Date of Electronic Publication: </i>2023 Nov 03. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37923752 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41467-023-42635-2 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 7053 Titles: – TitleFull: Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Rediti M – PersonEntity: Name: NameFull: Fernandez-Martinez A – PersonEntity: Name: NameFull: Venet D – PersonEntity: Name: NameFull: Rothé F – PersonEntity: Name: NameFull: Hoadley KA – PersonEntity: Name: NameFull: Parker JS – PersonEntity: Name: NameFull: Singh B – PersonEntity: Name: NameFull: Campbell JD – PersonEntity: Name: NameFull: Ballman KV – PersonEntity: Name: NameFull: Hillman DW – PersonEntity: Name: NameFull: Winer EP – PersonEntity: Name: NameFull: El-Abed S – PersonEntity: Name: NameFull: Piccart M – PersonEntity: Name: NameFull: Di Cosimo S – PersonEntity: Name: NameFull: Symmans WF – PersonEntity: Name: NameFull: Krop IE – PersonEntity: Name: NameFull: Salgado R – PersonEntity: Name: NameFull: Loi S – PersonEntity: Name: NameFull: Pusztai L – PersonEntity: Name: NameFull: Perou CM – PersonEntity: Name: NameFull: Carey LA – PersonEntity: Name: NameFull: Sotiriou C IsPartOfRelationships: – BibEntity: Dates: – D: 03 M: 11 Text: 2023 Nov 03 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 2041-1723 Numbering: – Type: volume Value: 14 – Type: issue Value: 1 Titles: – TitleFull: Nature communications Type: main |
| ResultId | 1 |
